Mundipharma today announced that Targin (Targinact, Targiniq), a fixed combination of prolonged-release oxycodone/naloxone, has received a positive European Commission decision for a new indication, as a second line symptomatic treatment for patients with severe to very severe idiopathic restless legs syndrome (RLS), after failure of dopaminergic therapy.

Oxycodone/naloxone is the first opioid which has been granted a licence in the EU for the treatment of RLS. This new licence indication provides a viable treatment option for patients who cannot tolerate the existing available treatments or who are not able to gain the level of symptom relief required.

Up until now, symptomatic treatment of idiopathic RLS included mainly dopamine agonists or dopaminergic substances such as L-dopa, however long-term use can lead to worsening of the symptoms in many individuals.

For more details, go to: http://www.reuters.com/article/2015/01/07/mundipharma-idUSnBw075327a+100+BSW20150107